Boston Scientific announces results for fourth quarter and full year 2024

Core Insights - Boston Scientific Corporation reported net sales of $4.561 billion in Q4 2024, representing a growth of 22.4% on a reported basis, 23.1% operationally, and 19.5% organically compared to the previous year [1][9] - For the full year 2024, the company achieved net sales of$ 16.747 billion, an increase of 17.6% reported, 18.5% operationally, and 16.4% organically [2][12] - The company’s GAAP net income for Q4 2024 was $566 million or$ 0.38 per share, up from $504 million or$ 0.34 per share a year earlier, with adjusted EPS of $0.70 compared to$ 0.55 [1][9] - The CEO highlighted 2024 as one of the best years in the company's history, driven by an innovative portfolio and significant clinical achievements [3] Financial Performance - Q4 2024 net sales by segment included: MedSurg (12.4% reported), Cardiovascular (28.8% reported), and Urology (19.5% reported) [9][10] - Regional performance in Q4 2024 showed the U.S. with a 30.7% increase, EMEA at 10.8%, APAC at 11.1%, and LACA at 4.6% [9][10] - For the full year 2024, the U.S. contributed $10.210 billion in sales, a 21.2% increase, while EMEA and APAC saw increases of 13.0% and 11.9% respectively [12][12] Recent Developments - The company presented positive clinical trial findings for the WATCHMAN FLX™ device and the FARAPULSE™ system, indicating advancements in treatment efficacy [9][10] - Boston Scientific received FDA approval for new products, including the Vercise™ Cartesia™ leads and AGENT™ Drug-Coated Balloon, enhancing its product offerings [9][10] - The company completed acquisitions of Axonics, Inc. and Cortex, Inc., expanding its capabilities in medical technology [9][10] Guidance - For 2025, Boston Scientific estimates net sales growth of approximately 12.5% to 14.5% on a reported basis and 10% to 12% organically [14][15] - The company projects GAAP EPS for 2025 to be in the range of$ 1.86 to $1.93, with adjusted EPS expected between$ 2.80 and $2.87 [14][16]